Novo Nordisk, Roche see outsized threats from U.S. drug pricing talks: analysts

Novo Nordisk, Roche see outsized threats from U.S. drug pricing talks: analysts

Source: 
Fierce Pharma
snippet: 

While Congress and the U.S. government have sought to lower drug prices for years, the issue appears to be coming to a head once again in Washington, D.C. The proposals that officials are eyeing aren’t new, but they could have outsized effects on some of the industry's largest players.


Analyzing the potential effects of drug pricing reform for European big pharma companies including AstraZeneca, Novartis and Sanofi, the team of analysts at ODDO BHF thinks Roche and Novo Nordisk stand to lose the most under the pricing proposals being discussed.